GC012F (AZD0120)

A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma

What's the purpose of the trial?

This trial is a phase 1, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CAR T-cell therapy, in early-line treatment in subjects with Multiple Myeloma.

Trial status

Accepting patients

Phase

Phase 1

Enrollment

18

Last Updated

1 day ago

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

AZD0120

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

GC012F (AZD0120): Newly Diagnosed Patients

Accepting patients

GC012F (AZD0120): Early Relapsed or Primary Refractory Patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.